Another inactivated vaccine developed by The Wuhan Institute of Biological Products can be made commercially available by late December 2020, as per Liu Jingzhen, who is the head of the state-owned Chinese company Sinopharm. As of now, this Chinese vaccine candidate is in its Phase III of human trials, which are the critical, last stage trials before a vaccine candidate is given regulatory approvals.